Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2006-10-30 Interim / Quarterly Rep…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Commitments Test Entity - First Quarter Report 7 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "Quarterly Report July - September 2006" and includes detailed financial data such as consolidated statement of cash flows, cash flows related to operating, investing, and financing activities, and payments to directors. It also references the quarter ended 30 September 2006. The presence of substantive financial data and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2006-10-30 English
Avian influenza vaccine efficacy trials 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 30 October 2006 regarding the commencement of efficacy trials for avian influenza vaccine candidates by Imugene Limited. It provides detailed information about the vaccine candidates, the trial site, and the company background. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a corporate announcement about a product development milestone and trial initiation, not a financial report, regulatory filing, or meeting material. Therefore, it fits best under the category of a general regulatory announcement or corporate update that does not fit other specific categories, which corresponds to Regulatory Filings (RNS). The document length (7812 characters) and content confirm it is not a brief report publication announcement or a full financial report.
2006-10-29 English
Annual Report 75 pages ?Kb
Annual Report Classification · 95% confidence The document is titled as an Annual Report for the year 2006 for Imugene Limited. It contains detailed sections typical of an annual report such as Chairman's Report, Executives' Report, Directors' Report, Remuneration Report, Independent Audit Report, Income Statement, Balance Sheet, Cash Flow Statement, Statement of Changes in Equity, Notes to the Financial Statements, Directors' Declaration, Corporate Governance, and Shareholder Information. The presence of comprehensive financial statements and detailed management commentary confirms this is a full yearly report covering company activity and financial performance. The length of the document (15,000 characters) and the detailed content further support classification as an Annual Report rather than an announcement or summary. Therefore, the appropriate filing type is Annual Report (10-K).
2006-10-25 English
Notice of Annual General Meeting 6 pages ?Kb
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' for Imugene Limited, specifying the date, time, and location of the AGM. It includes the agenda items such as receiving the financial report, adopting the remuneration report, and re-election of a director. It also contains proxy forms and explanatory statements related to the AGM. There is no actual financial data or detailed financial statements included, only references to the Annual Report and financial report to be received at the meeting. The document serves as a notice and informational material for shareholders to prepare for the AGM, not the report itself. Therefore, it fits the category of AGM Information (AGM-R).
2006-10-25 English
Poultry Productivity Enhancer Passes Further Safety Trials 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 20 October 2006 regarding the completion of safety trials for a poultry vaccine product. It discusses trial results, regulatory approval processes, and company information. The content is a brief update on product development and regulatory progress rather than a detailed financial report, management discussion, or regulatory filing. The document length is short (2905 characters) and it is clearly an announcement of trial results and regulatory submission plans, not a full report or financial statement. There is no indication of financial data, earnings, board changes, or voting results. Therefore, the document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2006-10-19 English
Full Year Accounts 51 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'Financial Report For The Year Ended 30 June 2006' and contains detailed sections typical of an annual report, including Directors' report, Remuneration report, Auditors' independence declaration, Independent audit report, Income statement, Balance sheet, Cash flow statement, Statement of changes in equity, Notes to the financial statements, and Directors' declaration. The presence of comprehensive financial statements and detailed corporate information for a full fiscal year strongly indicates this is a full Annual Report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K).
2006-09-17 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.